<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01955239</url>
  </required_header>
  <id_info>
    <org_study_id>RT2011-04</org_study_id>
    <nct_id>NCT01955239</nct_id>
  </id_info>
  <brief_title>Parotid-gland Stem-cell Sparing Intensity-modulated Radiotherapy</brief_title>
  <acronym>SCS-IMRT</acronym>
  <official_title>Prevention of Radiation-induced Parotid Gland Dysfunction by Parotid-gland Stem-cell Sparing Intensity-modulated Radiotherapy(SCS-IMRT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale:

      Radiation-induced parotid gland dysfunction, often leading to xerostomia is the
      most-frequently occurring side-effect with a major impact on patient-reported quality of life
      after radiotherapy for head and neck cancer (HNC). Therefore, treatments for HNC are
      currently optimized to minimize the mean dose to the parotid glands. Though this resulted in
      a significant reduction of toxicity, 30%-40% of the patients still develop sustained parotid
      gland dysfunction and xerostomia.

      However, in animal studies the investigators found that the dose to the sub-volume of the
      gland containing the parotid gland stem cells is a better predictor for dysfunction than the
      mean dose to the whole gland. Subsequently, this finding was confirmed in a retrospective
      analysis in patients. Therefore, a reduction of dose specifically in this sub-volume of the
      parotid glands of patients is expected to further reduce the risk of parotid gland
      dysfunction and xerostomia.

      Objective:

      To test the hypothesis that parotid gland stem cell sparing intensity modulated radiotherapy
      in HNC patients reduces the risk of parotid gland dysfunction and xerostomia as compared to
      conventional parotid gland sparing intensity modulated radiotherapy.

      Study design:

      Double-blind prospective randomized trial (51 patients per arm). Study population: Patients
      treated for tumours in the head-and-neck region with curative radiotherapy, with or without
      the addition of chemotherapy or cetuximab.

      Intervention: Patients randomized into the experimental arm will receive a treatment in which
      the radiation dose to the parotid gland is re-distributed to minimize dose to the sub-volume
      containing the stem cells, while keeping the same mean dose to the parotid gland as a whole.

      Main study parameters/endpoints:

      Primary endpoint is parotid gland salivary secretion. Secondary endpoints are patient- and
      physician-rated xerostomia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Salivary flow</measure>
    <time_frame>12 months after radiotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient-rated Xerostomia</measure>
    <time_frame>12 months after radiotherapy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Standard IMRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard IMRT in which the mean dose to both whole parotid glands is minimized.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stem-cell Sparing IMRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stem-cell Sparing IMRT in which the mean dose to the stem cell containing region of the parotid gland is minimized</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-modulated Radiotherapy</intervention_name>
    <arm_group_label>Standard IMRT</arm_group_label>
    <arm_group_label>Stem-cell Sparing IMRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Squamous cell carcinoma originating from the mucosa of the head and neck area or
             nasopharyngeal carcinoma originating from the nasopharynx;

          -  The radiotherapy includes prophylactic or therapeutic irradiation of both sides of the
             neck (at least level II to IV);

          -  Age â‰¥ 18 years;

          -  WHO performance 0-2;

          -  To reduce the uncertainty in the assessment of relative flow after treatment,
             pre-treatment parotid gland saliva production stimulated with 5% citric acid should
             exceed &gt;0.1 ml/min

        Exclusion Criteria:

          -  Postoperative radiotherapy;

          -  Previous radiotherapy of the head and neck region (re-irradiation);

          -  Unilateral radiotherapy;

          -  Primary salivary gland tumours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, Leemans CR, Aaronson NK, Slotman BJ. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol. 2008 Aug 1;26(22):3770-6. doi: 10.1200/JCO.2007.14.6647.</citation>
    <PMID>18669465</PMID>
  </reference>
  <reference>
    <citation>Beetz I, Schilstra C, van der Schaaf A, van den Heuvel ER, Doornaert P, van Luijk P, Vissink A, van der Laan BF, Leemans CR, Bijl HP, Christianen ME, Steenbakkers RJ, Langendijk JA. NTCP models for patient-rated xerostomia and sticky saliva after treatment with intensity modulated radiotherapy for head and neck cancer: the role of dosimetric and clinical factors. Radiother Oncol. 2012 Oct;105(1):101-6. doi: 10.1016/j.radonc.2012.03.004. Epub 2012 Apr 18.</citation>
    <PMID>22516776</PMID>
  </reference>
  <reference>
    <citation>Eisbruch A. Radiotherapy: IMRT reduces xerostomia and potentially improves QoL. Nat Rev Clin Oncol. 2009 Oct;6(10):567-8. doi: 10.1038/nrclinonc.2009.143.</citation>
    <PMID>19787001</PMID>
  </reference>
  <reference>
    <citation>Konings AW, Cotteleer F, Faber H, van Luijk P, Meertens H, Coppes RP. Volume effects and region-dependent radiosensitivity of the parotid gland. Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1090-5.</citation>
    <PMID>15990013</PMID>
  </reference>
  <reference>
    <citation>Konings AW, Faber H, Cotteleer F, Vissink A, Coppes RP. Secondary radiation damage as the main cause for unexpected volume effects: a histopathologic study of the parotid gland. Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):98-105. Epub 2005 Oct 13.</citation>
    <PMID>16226398</PMID>
  </reference>
  <reference>
    <citation>Lombaert IM, Brunsting JF, Wierenga PK, Faber H, Stokman MA, Kok T, Visser WH, Kampinga HH, de Haan G, Coppes RP. Rescue of salivary gland function after stem cell transplantation in irradiated glands. PLoS One. 2008 Apr 30;3(4):e2063. doi: 10.1371/journal.pone.0002063.</citation>
    <PMID>18446241</PMID>
  </reference>
  <reference>
    <citation>Lombaert IM, Brunsting JF, Wierenga PK, Kampinga HH, de Haan G, Coppes RP. Keratinocyte growth factor prevents radiation damage to salivary glands by expansion of the stem/progenitor pool. Stem Cells. 2008 Oct;26(10):2595-601. doi: 10.1634/stemcells.2007-1034. Epub 2008 Jul 31.</citation>
    <PMID>18669914</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2013</study_first_submitted>
  <study_first_submitted_qc>October 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2013</study_first_posted>
  <last_update_submitted>June 21, 2017</last_update_submitted>
  <last_update_submitted_qc>June 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Roel Steenbakkers</investigator_full_name>
    <investigator_title>M.D., Ph.D.</investigator_title>
  </responsible_party>
  <keyword>Head and Neck Cancer</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>IMRT</keyword>
  <keyword>Stem cell</keyword>
  <keyword>Parotid gland</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

